Marshall, C. H., Park, J. C., Fu, W., Wang, H., DeWeese, T. L., King, S., … Antonarakis, E. S. (2020). Results of the randomized phase II study of sipuleucel-T (Sip-T) +/- Radium-223 (Ra-223) in men with bone-metastatic castration resistant prostate cancer. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).

Marshall, Catherine Handy, Jong Chul Park, Wei Fu, Hao Wang, Theodore L. DeWeese, Serina King, Michaella Afful, et al. “Results of the randomized phase II study of sipuleucel-T (Sip-T) +/- Radium-223 (Ra-223) in men with bone-metastatic castration resistant prostate cancer.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.

Marshall CH, Park JC, Fu W, Wang H, DeWeese TL, King S, et al. Results of the randomized phase II study of sipuleucel-T (Sip-T) +/- Radium-223 (Ra-223) in men with bone-metastatic castration resistant prostate cancer. In: JOURNAL OF CLINICAL ONCOLOGY. 2020.

Marshall, Catherine Handy, et al. “Results of the randomized phase II study of sipuleucel-T (Sip-T) +/- Radium-223 (Ra-223) in men with bone-metastatic castration resistant prostate cancer.” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.

Marshall CH, Park JC, Fu W, Wang H, DeWeese TL, King S, Afful M, Hurrelbrink J, Manogue C, Cotogno P, Moldawer NP, Barata PC, Drake CG, Posadas EM, Armstrong AJ, Sartor AO, Antonarakis ES. Results of the randomized phase II study of sipuleucel-T (Sip-T) +/- Radium-223 (Ra-223) in men with bone-metastatic castration resistant prostate cancer. JOURNAL OF CLINICAL ONCOLOGY. 2020.